The Question Every Trial Sponsor Faces
A pharmaceutical company is designing a Phase III diabetes trial. The protocol calls for participants to complete detailed questionnaires at enrollment and then quarterly for nine months. The study team needs to determine compensation. Someone suggests a nominal payment, maybe enough to cover parking and time. Someone else worries about setting it too high and creating undue inducement concerns.
This is where most trial sponsors get stuck. The regulatory framework warns against payments that could coerce participation or cloud judgment. Fair enough. But that leaves a massive gray area between "token gesture" and "excessive inducement."
The real question is not how little you can pay without looking cheap. The real question is what the participant contribution is actually worth. And here is what most sponsors miss: the person living with type 2 diabetes for a decade is not just a data point. They are the expert you need.
The Old Model: Participants as Passive Subjects
Clinical trial compensation has historically been treated as reimbursement for inconvenience. Show up to the site, sit for a blood draw, maybe fill out a short form. The payment was a courtesy, something to cover your parking or acknowledge the hassle of scheduling around the visit.
This model reflected how trials were designed. Participants were subjects in the truest sense. The research happened to them. They were recipients of an intervention, providers of a biological sample, answerers of simple questions. The expertise lived entirely with the investigators.
That framing made compensation easy to justify. You were not paying for specialized knowledge. You were offsetting the minor burden of participation. A nominal amount felt appropriate because the participant role itself was nominal.
The New Reality: Participants as Expert Contributors
Modern trials, especially in chronic disease management, look fundamentally different. Participants are not just showing up for a blood draw. They are actively generating rich, longitudinal data that reflects the complexity of living with their condition.
Take that diabetes study. Participants might be using continuous glucose monitors, logging meals and physical activity, reporting on symptoms and quality of life through detailed surveys. Each touchpoint requires thoughtful engagement. Each response draws on years of lived experience managing the disease.
Who understands the fear of hypoglycemia better than someone who has experienced it repeatedly? Who can more accurately describe the daily burden of glucose monitoring, the anxiety around social eating, the fatigue that comes with poor control? That knowledge is not incidental. It is the data you are collecting.
This is where the traditional compensation model breaks down. You are not reimbursing someone for a minor inconvenience. You are engaging an expert in their disease state. The person who has managed diabetes for ten years brings a depth of insight that no investigator, no matter how clinically experienced, can replicate. They know what it feels like. They know what works and what does not. They know the unspoken challenges that never make it into a clinical note.
That expertise has value. Real, measurable, defensible value. Treating it as anything less does not just disrespect the participant. It undermines the quality of your research.
The Regulatory Concern: Undue Inducement
IRBs and regulators worry about undue inducement for good reason. If you pay participants so much that they feel compelled to enroll despite reservations, you have crossed an ethical line. You are buying compliance, not informed consent.
But here is the tension: that concern has often been interpreted as a reason to keep payments low. The logic goes that if you barely pay anything, you cannot possibly be coercing anyone. The problem with that logic is it assumes participants have no legitimate reason to value their contribution. It assumes fair compensation and coercion are the same thing.
They are not.
Coercion happens when payment is so excessive relative to the burden that it distorts decision making. Fair compensation happens when payment reflects the actual value of what the participant provides. The difference matters.
A person with a chronic disease who chooses to participate in research because they are fairly compensated for their time and expertise is not being coerced. They are making an informed economic decision. They are trading their knowledge and effort for appropriate payment, the same way any professional consultant would.
The key is defensibility. Can you explain why you are paying what you are paying? Is it grounded in a rational assessment of the time required, the expertise involved, and the value delivered? Or is it based on gut feel, competitive guesswork, or a vague sense of what "seems reasonable"?
If you cannot defend your payment structure with rigor, you are vulnerable. Not just to IRB questions, but to the deeper problem of treating participants as something other than the experts they are.
Building a Defensible Compensation Model
The shift in thinking is straightforward: stop treating participants as subjects receiving a stipend and start treating them as expert contributors providing a professional service.
That shift requires a compensation model grounded in something more rigorous than competitive benchmarking or internal budget constraints. It requires recognizing that participants bring varying levels of expertise to the table and that expertise matters.
A newly diagnosed patient brings valuable perspective, but someone who has managed their condition for years brings deeper insight. Someone who has navigated multiple treatment failures, who understands the nuances of symptom patterns, who can articulate what daily management actually looks like, is providing a level of expertise that deserves recognition.
A defensible model accounts for this. It segments participants by expertise level. It considers the actual time burden involved, not just the time spent on study tasks but the cognitive load of thoughtful engagement. It applies the same principles you would use to value any professional service: direct costs, indirect costs, and a margin that reflects the specialized knowledge being provided.
This is not about paying the maximum you can justify. This is about paying what the service is actually worth. And when you approach it that way, you are not guessing. You are building a compensation structure that can withstand scrutiny because it is rooted in rational valuation principles, not arbitrary benchmarks or budget convenience.
The output is not a single number. It is a defensible range that reflects the variability in participant expertise and time commitment. That range gives you flexibility while maintaining rigor. More importantly, it gives you a clear answer when an IRB asks why you are paying what you are paying.
Why This Approach Works
Fair compensation does more than satisfy IRB requirements. It changes the entire dynamic of trial participation.
When you pay someone appropriately for their expertise, you signal respect. You acknowledge that their lived experience matters, that their contribution is essential, and that you value their time. That signal matters to recruitment. It matters to retention. It matters to data quality.
Participants who feel fairly compensated are more engaged. They complete questionnaires more thoughtfully. They are more likely to stick with the study through to completion. They are more willing to recommend the trial to others in their community. All of this translates directly to better research outcomes.
Beyond that, it creates a record that holds up under scrutiny. When an IRB or regulatory body questions your compensation structure, you do not point to what a competitor is paying or what "feels right." You point to a formal analysis grounded in established valuation principles. You explain the time burden, the expertise required, and the methodology used to arrive at fair market value.
That level of rigor does not just protect you from regulatory risk. It elevates the entire conversation around participant compensation. It moves the discussion from "How little can we pay?" to "What is this contribution actually worth?" That is the right question.
The Bigger Picture
The life sciences industry has spent decades refining how it values almost everything: IP, manufacturing capacity, distribution networks, clinical endpoints. Participant compensation has lagged behind, treated as an administrative detail rather than a strategic decision.
That needs to change. As trials become more complex, as patient reported outcomes carry more weight, as real world evidence becomes central to regulatory submissions, the expertise participants bring becomes more valuable. Recognizing that value is not just ethically sound. It is strategically smart.
Participants are not test subjects. They are not data points. They are experts in their disease state, and they deserve to be compensated accordingly. Get that right, and everything else becomes easier. Get it wrong, and you are building your research on a foundation that does not hold.
The choice is straightforward: treat participants as valuable contributors and pay them accordingly, or continue with outdated models that disrespect their expertise and undermine your research. Only one of those approaches is defensible.